These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34613603)

  • 21. Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan.
    Pumford AD; Bauman M; Bouchal S; Riviere-Cazaux C; Jusue-Torres I; Hong S; Neth BJ; Sener U; Parney IF
    World Neurosurg; 2024 Oct; 190():291-296. PubMed ID: 39094939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
    Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
    Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
    Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
    J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Peltola K; de Velasco G; Burotto M; Suarez C; Ghatalia P; Iacovelli R; Lam ET; Verzoni E; Gümüş M; Stadler WM; Kollmannsberger C; Melichar B; Venugopal B; Gross-Goupil M; Poprach A; De Santis M; Schutz FA; Park SH; Nosov DA; Porta C; Lee JL; Garcia-Del-Muro X; Biscaldi E; Manneh Kopp R; Oya M; He L; Wang A; Perini RF; Vickery D; Albiges L; Rini B;
    N Engl J Med; 2024 Aug; 391(8):710-721. PubMed ID: 39167807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
    Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
    Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
    Tella SH; Taïeb D; Pacak K
    Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
    David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
    Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting HIF-2 Alpha in Renal Cell Carcinoma.
    Ahmed R; Ornstein MC
    Curr Treat Options Oncol; 2023 Sep; 24(9):1183-1198. PubMed ID: 37403008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
    Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
    Williams C; Walther M
    ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
    Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma.
    Nguyen CB; Oh E; Bahar P; Vaishampayan UN; Else T; Alva AS
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exceptional and Sustained Response to Belzutifan in Von Hippel-Lindau Disease-Associated Central Nervous System Hemangioblastoma.
    Thalji M; Vadlapatla V; Avgeropoulos NG; Ramakrishna N; Baidas S
    Cureus; 2024 Jan; 16(1):e52979. PubMed ID: 38406059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.